- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01729884
Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer
Phase II Study to Evaluate the Development of HER2/Neu (HER2)-Specific Memory T Cells After HER2 Peptide-based Vaccination in Patients With Advanced Stage Her2+ Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To quantify and characterize human epidermal growth factor receptor 2 (HER2)-specific central memory T cell (TCM) and effector memory T cell (TEM) subsets in peripheral blood mononuclear cell (PBMC) of patients vaccinated with a HER2 cytotoxic T lymphocyte (CTL) peptide-based vaccine.
II. To evaluate the feasibility of expanding HER2-specific effector T cells (TE) derived from HER2-specific TCM or TEM precursors in patients vaccinated with a HER2 CTL peptide-based vaccine and characterize their function.
SECONDARY OBJECTIVES:
I. To evaluate the safety of administering a HER2 CTL peptide-based vaccine in patients who are receiving trastuzumab and/or lapatinib (lapatinib ditosylate).
OUTLINE:
Patients receive HER-2/neu peptide vaccine intradermally (ID) once monthly for 3 months.
After completion of study treatment, patients are followed up at 4 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with HER2+ stage IV breast cancer that have been maximally treated and not in a complete remission
Patients must have measurable disease per imaging studies performed within 60 days of enrollment as described below:
- Extra skeletal disease that can be measured with conventional or spiral computed tomography (CT) techniques
- Skeletal or bone-only disease that is measurable by fludeoxyglucose F 18 (FDG) positron emission tomography (PET) or magnetic resonance imaging (MRI)
- Patients can be receiving trastuzumab and/or lapatinib and/or hormonal therapy and/or bisphosphonate therapy
- HER2 overexpression in the primary tumor or metastasis by immunohistochemistry (IHC) of 3+, or documented gene amplification by fluorescent in situ hybridization (FISH) analysis
- Patients must be human leukocyte antigen (HLA)-A2 positive
- Eastern Cooperative Oncology Group (ECOG)/Zubrod scale of =< 1
- Patients must be off immunosuppressive treatments (i.e., chemotherapy or systemic steroids) 3 weeks prior to first vaccine
- Patients on trastuzumab must have a baseline left ventricular ejection fraction (LVEF) measured by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) >= the lower limit of normal for the facility within 3 months of enrollment to study
- Subjects of reproductive ability must agree to use contraceptives during the entire study period
Exclusion Criteria:
- White blood cell (WBC) < 3000/mm^3
- Hemoglobin (Hgb) < 10 mg/dl
- Platelets < 100,000/mm^3
- Serum creatinine > 2.0 mg/dl
- Serum bilirubin > 1.5 x upper limit of normal
- Any contraindication to receiving sargramostim (GM-CSF) based vaccine products
- Concurrent enrollment in other treatment studies
- New York Heart Association functional class III-IV heart failure, symptomatic pericardial effusion, or unstable angina
- Pregnant or breast-feeding women
- History of disorders associated with immunosuppression such as human immunodeficiency virus (HIV)
- Active brain metastasis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment (HER-2/neu peptide vaccine)
Patients receive HER-2/neu peptide vaccine ID once monthly for 3 months.
|
Given ID
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantification and characterization of HER2-specific TCM and TEM subsets in PBMC
Time Frame: Up to 4 weeks
|
Wilson score 90% confidence intervals will be reported.
|
Up to 4 weeks
|
Evaluation of function and phenotype of HER2-specific TE cells derived from HER2-specific TCM and TEM subsets
Time Frame: Up to 4 weeks
|
Wilson score 90% confidence intervals will be reported.
Determined by flow cytometry and reported using descriptive statistics and graphical summaries.
|
Up to 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of subjects reporting adverse events, evaluated according to the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Time Frame: Up to 4 weeks
|
All, severe or worse, serious and related events will be quantified.
|
Up to 4 weeks
|
The percent of subjects recording adverse events, evaluated according to the CTEP CTCAE version 4.0
Time Frame: Up to 4 weeks
|
All, severe or worse, serious and related events will be quantified.
|
Up to 4 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7905 (OTHER: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium)
- P30CA015704 (U.S. NIH Grant/Contract)
- P50CA138293 (U.S. NIH Grant/Contract)
- NCI-2012-02223 (REGISTRY: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER2-positive Breast Cancer
-
Mersana TherapeuticsRecruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast CancerUnited States
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
MacroGenicsApproved for marketingHER2-positive Breast Cancer | HER2-positive Carcinoma
-
Spanish Breast Cancer Research GroupSeagen Inc.RecruitingHER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast CarcinomaSpain
-
Cancer Trials IrelandCompletedBreast Cancer | HER2 Positive Breast Cancer | HER2 Negative Breast CancerIreland
-
University of ArizonaPfizerCompletedBreast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | Recurrent Breast Cancer | HER2 Positive Breast Carcinoma | Breast Cancer StageUnited States
-
Enliven TherapeuticsRecruitingColorectal Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2 Amplification | HER2 Positive Solid TumorsUnited States
-
Daiichi SankyoRecruitingBreast Cancer | Advanced Cancer | HER2-positive Breast Cancer | HER2-low Breast CancerChina
-
Ruth O'ReganUniversity of Rochester; Puma Biotechnology, Inc.RecruitingBreast Cancer | HER2-positive Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast CancerUnited States
-
BioInvent International ABActive, not recruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast CancerSpain, United Kingdom, Germany
Clinical Trials on HER-2/neu peptide vaccine
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage IV Breast Cancer | HER2/Neu Positive | HLA-A2 Positive Cells Present | Stage IV Ovarian CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)Completed
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of PennsylvaniaAbramson Cancer Center of the University of PennsylvaniaNo longer availableMetastatic CancerUnited States
-
University of WashingtonCompletedBreast Cancer | Ovarian Cancer | Lung CancerUnited States
-
University of WashingtonCompletedBreast Cancer | Ovarian Cancer | Lung CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Ontario Clinical Oncology Group (OCOG)Canadian Breast Cancer Research Alliance; Ontario Cancer Research NetworkCompletedMetastatic Breast Cancer | Recurrent Breast CancerCanada
-
Mayo ClinicNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Craig L Slingluff, JrNational Cancer Institute (NCI)CompletedEvaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer (Breast 37)Breast NeoplasmsUnited States